SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-019398
Filing Date
2022-10-07
Accepted
2022-10-07 17:09:31
Documents
13
Period of Report
2022-10-05
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20221005.htm   iXBRL 8-K 55823
  Complete submission text file 0000950170-22-019398.txt   207249

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sabs-20221005.xsd EX-101.SCH 3214
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sabs-20221005_def.xml EX-101.DEF 13467
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sabs-20221005_pre.xml EX-101.PRE 12759
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sabs-20221005_lab.xml EX-101.LAB 17250
7 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20221005_htm.xml XML 6479
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 221301423
SIC: 2836 Biological Products, (No Diagnostic Substances)